Dates: March 17-21, 2026
Location: Copenhagen, Denmark
Organizer: Kenes Group
Company presentations at AD/PD 2026 provided a platform for pharmaceutical and biotechnology companies to showcase their research programs, clinical trial results, and pipeline updates for both Alzheimer's disease and Parkinson's disease therapies.
Companies presented data on amyloid-targeting therapies:
- Eisai/Biogen — Leqembi (lecanemab) real-world data and ongoing studies
- Eli Lilly — Donanemab trajectory and regulatory status
- Roche/Genentech — Gantenerumab and anti-amyloid pipeline updates
Tau-targeted approaches were prominently featured:
- AbbVie — Tau immunotherapy programs
- ** Eli Lilly** — Tau PET tracer and therapeutic development
¶ Neuroprotection and Symptomatic Treatments
Additional therapeutic approaches:
- Axsome Therapeutics — AXS-05 and CNS pipeline
- Biogen — ALS and dementia pipeline
Companies highlighted alpha-synuclein-directed programs:
- Roche — Anti-alpha-synuclein antibodies
- Biogen — Gene therapy approaches
Genetic-driven therapeutic development:
- Denali Therapeutics — LRRK2 inhibitor programs
- Neuraly — GBA-targeted approaches
Motor and non-motor symptom management:
- AbbVie — Dyskinesia management
- Acorda Therapeutics — Ampyra and pipeline
- Prothelia — Proteostasis modulators
- Catapult Therapeutics — Novel small molecules
- Asceneuron — Tau aggregation inhibitors
¶ Gene and Cell Therapy
- Voyager Therapeutics — Gene therapy programs
- BlueRock Therapeutics — Cell therapy approaches
- Aspen Neuroscience — Autologous cell therapy
¶ Biomarker and Diagnostics
- C2N Diagnostics — PrecivityAD and fluid biomarkers
- Fujirebio — Lumipulse platform
- Roche Diagnostics — Neurology biomarker portfolio
- Antibody suppliers
- Contract research organizations
- Animal model providers
- Imaging services
- Biomarker laboratories
- Clinical trial management
- AI/ML for drug discovery
- Data analytics platforms
- Digital health solutions
Industry-sponsored educational sessions covered:
- Clinical trial design innovations
- Biomarker-driven patient selection
- Regulatory perspectives
- Real-world evidence approaches
The AD/PD 2026 conference showcased a robust pipeline across multiple therapeutic modalities:
| Modality |
AD Programs |
PD Programs |
| Monoclonal Antibodies |
15+ |
8+ |
| Small Molecules |
20+ |
25+ |
| Gene Therapy |
5+ |
10+ |
| Cell Therapy |
3+ |
6+ |
- Amyloid continues to dominate — Anti-amyloid antibodies remain the most advanced AD therapeutic approach
- Tau gaining momentum — Increasing investment in tau-targeted therapies
- PD pipeline diverse — Multiple approaches targeting alpha-synuclein, LRRK2, and GBA
- Biomarker integration — Industry increasingly incorporating biomarkers in clinical development
- Combination approaches — Growing interest in multi-target strategies